Telehealth Allied Health Care With People Who Have Parkinson's Disease Living in Rural Nevada and Wyoming
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03381898|
Recruitment Status : Recruiting
First Posted : December 22, 2017
Last Update Posted : December 22, 2017
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Behavioral: Telehealth Exercise, speech therapy, medication management||Not Applicable|
Parkinson's Disease & Allied Health. Parkinson's disease (PD), the second most common neurodegenerative disorder affecting more than a million people in the U.S., has no known cause or cure. Persons with PD use prescription medications and behavioral interventions to alleviate key problems such as walking, handling objects, and speaking. Individuals with PD, accessing multidisciplinary allied health care intervention, have shown functional gains. Without these ongoing, coordinated services, persons with PD become even more debilitated, and this can hasten a decline in their quality of life.
Parkinson's Disease & Rurality. For those in rural areas, there is a critical health disparity. People who live rurally contend with isolation. Wyoming and Nevada's population density are ranked 49th and 42nd. In conjunction with this low population density and mountainous terrain, individuals experience tremendous burdens including traveling long distances to see health care providers with expertise in treating PD. These factors contribute to the struggle of rural Americans with PD to manage this complicated, chronic disease.
Parkinson's Disease & Telehealth. Telehealth technology has successfully allowed the delivery of neurology care via "virtual house calls" with rural residents with PD. The virtual house call model was determined to be feasible and promising for specialist care in underserved rural areas. However, telehealth delivery of allied health care should also be examined.
Thus, the investigators propose an exploratory Phase 2 Behavioral Clinical Trial to determine feasibility, safety, and signal of efficacy for telehealth coordinated allied health care for persons with Parkinson's disease in rural Wyoming and Nevada. All 20 participants will be in one arm receiving telehealth exercise, speech therapy, and medication management for eight weeks.
For persons with Parkinson's disease in rural Wyoming and Nevada, the investigators will:
Aim 1 Test the feasibility of speech therapy, exercise therapy and medication management coordinated through telehealth.
Aim 2 Determine the safety of the coordinated telehealth speech therapy, exercise therapy, and medication management.
Aim 3 Measure signal of efficacy for telehealth outcomes
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This is a feasibility and safety trial of a single arm a telehealth intervention (pharmacy, physical therapy, and speech therapy) to people with Parkinson's disease.|
|Masking:||None (Open Label)|
|Masking Description:||The outcomes assessment and the care providers will be blind to the aims of the study.|
|Official Title:||Decreasing Health Disparities for Parkinson's Disease in Rural Communities: Assessing Feasibility of Coordinated Telehealth to Deliver Allied Health Care of Medication Management, Physical Therapy, and Speech Therapy|
|Actual Study Start Date :||November 2, 2017|
|Estimated Primary Completion Date :||December 31, 2018|
|Estimated Study Completion Date :||May 31, 2019|
Experimental: Telehealth Coordinated Allied Health
rural persons with Parkinson's disease will receive telehealth exercise, speech therapy, medication management for 8 weeks. Exercise, speech therapy, and medication management are usual care for persons with Parkinson's disease. Having the 3 areas coordinated in delivery via telehealth is the new delivery that our aims address
Behavioral: Telehealth Exercise, speech therapy, medication management
Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
- Aim 1: Feasibility of the 8-week telehealth program [ Time Frame: 8 weeks ]The number of sessions completed and ability to use the necessary technology.
- Aim 2: Safety of the 8-week telehealth program [ Time Frame: 8 weeks ]The frequency and nature of adverse events during participation of the telehealth program.
- Aim 3: Change in Signal of efficacy of the telehealth program - overall [ Time Frame: 0, 8, 24 weeks ]The change in quality of life between baseline at the beginning of the study and after the 8 week intervention. In addition, change will also be measured between the end of the 8 week intervention and 18 weeks later (24 weeks from the baseline). This quality of life measures is a self-report, PD-specific Parkinson's Disease Questionnaire 39 (PDQ39). There are 39 items in 8 subsections (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, bodily discomfort). Each item ranges from 0 (never) to 4 (always). The overall score and subsection scores are calculated by taking the means of each item divided by the total for that section; thus, converting the score into a percentage with higher percentages equating to more disability.
- Aim 3: Signal of efficacy of the telehealth program - pharmacy [ Time Frame: 8, 24 weeks ]Change in pill count (i.e., how many pills of each prescription are taken) over the period of the study.
- Aim 3: Signal of efficacy of the telehealth program - physical therapy 1 [ Time Frame: 0, 8, 24 weeks ]Change in 30 second Sit-to-Stand test which measures how many times the participant can stand in 30 seconds.
- Aim 3: Signal of efficacy of the telehealth program - physical therapy 2 [ Time Frame: 0, 8, 24 weeks ]Change in Parkinson's Fatigue Scale, which is a self-report measure of fatigue. This scale measures 16 items using a Likert scale with a low score of 16 (low fatigue) and a high score of 80 (high fatigue).
- Aim 3: Signal of efficacy of the telehealth program - physical therapy 3 [ Time Frame: 0, 8, 24 weeks ]Change in Unified Parkinson's Disease Rating Scale II (UPDRS II), which is a self-report of PD-specific motor aspects of experiences of daily living. There are 13 items with scores ranging from 0 (normal) to 4 (severe). Thus, a score of 0 indicates normal function whereas a score of 52 (the highest possible score) suggestive of severe motor deficits with activities of daily living.
- Aim 3: Signal of efficacy of the telehealth program - speech therapy 1 [ Time Frame: 0, 8, 24 weeks ]Change in self-report Communication Effectiveness Scale, which is an 8 question scale using a 4-point likert scale on how the participant social participation is affected by his speech and communication. The scores range from 0 (not effective) to 32 (very effective communication in all situations).
- Aim 3: Signal of efficacy of the telehealth program - speech therapy 2 [ Time Frame: 0, 8, 24 weeks ]Change in Vocal sound level intensity using the Lee Silverman Voice Treatment (LSVT) Companion Software which measures speech intensity. Changes in vocal sound level could range from - 6 decibel (dB) (reduced loudness) to at least + 6dB which is the average change and is perceptually noticeable.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03381898
|Contact: Kathleen Nagle, LPNfirstname.lastname@example.org|
|United States, Nevada|
|University of Nevada Las Vegas||Recruiting|
|Las Vegas, Nevada, United States, 89154|
|Contact: Kathleen Nagle, LPN 702-895-1377 email@example.com|
|Sub-Investigator: Merrill Landers, DPT, PhD|
|United States, Wyoming|
|University of Wyoming||Recruiting|
|Laramie, Wyoming, United States, 82070|
|Contact: Kathleen Nagle, LPN 702-895-1055 firstname.lastname@example.org|
|Principal Investigator: Mary Jo Cooley Hidecker, PhD|
|Principal Investigator:||Mary Jo Cooley Hidecker, PhD||University of Wyoming|
|Study Director:||Merrill Landers, DPT, Ph.D.||University of Nevada, Las Vegas|